ArticleFrontiers in medicine2026
Phosphaturic mesenchymal tumor in the temporalis muscle causing tumor-induced osteomalacia: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia, and impaired bone mineralization, primarily caused by phosphaturic mesenchymal tumors (PMTs). Due to the small size and non-specific clinical presentation, PMTs are often difficult to localize, resulting in delayed diagnosis. This study presents a case of a 54-year-old man who experienced a 2-year history of progressive polyarthralgia affecting the knees, hips, and lower back, which exacerbated over the past 3 months. Laboratory tests revealed hypophosphatemia, elevated alkaline phosphatase (ALP) levels, and increased parathyroid hormone (PTH) levels. Moreover, a dual-energy X-ray absorptiometry (DXA) scan indicated low bone mineral density (BMD), while a whole-body bone scintigraphy revealed multiple rib pathological fractures, indicative of osteomalacia. Although serum fibroblast growth factor 23 (FGF23) was not measured, the clinical and biochemical profiles were highly consistent with tumor-induced osteomalacia (TIO). Subsequent Gallium-68 1,4,7,10-tetraazacyclododecane 1,4,7,10-tetraacetic acid tyrosine-3-octreotate positron emission tomography/computed tomography (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.